46.25
Schlusskurs vom Vortag:
$45.64
Offen:
$45.31
24-Stunden-Volumen:
2.08M
Relative Volume:
0.96
Marktkapitalisierung:
$5.73B
Einnahmen:
$692.26M
Nettoeinkommen (Verlust:
$-512.41M
KGV:
-10.91
EPS:
-4.24
Netto-Cashflow:
$-274.36M
1W Leistung:
-3.83%
1M Leistung:
-5.88%
6M Leistung:
-2.01%
1J Leistung:
+44.53%
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Vergleichen Sie GH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GH
Guardant Health Inc
|
46.25 | 5.96B | 692.26M | -512.41M | -274.36M | -4.24 |
![]()
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-10 | Eingeleitet | Mizuho | Outperform |
2025-01-23 | Eingeleitet | Barclays | Overweight |
2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
2024-06-03 | Fortgesetzt | Jefferies | Buy |
2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
2023-12-14 | Eingeleitet | Guggenheim | Neutral |
2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-09-28 | Eingeleitet | Bernstein | Outperform |
2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
2023-05-05 | Eingeleitet | UBS | Buy |
2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-10-19 | Eingeleitet | Craig Hallum | Buy |
2022-10-06 | Eingeleitet | Stephens | Overweight |
2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
2022-04-28 | Fortgesetzt | BTIG Research | Buy |
2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
2022-02-24 | Bestätigt | Citigroup | Buy |
2022-02-24 | Bestätigt | Cowen | Outperform |
2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
2022-02-24 | Bestätigt | SVB Leerink | Outperform |
2022-02-24 | Bestätigt | Stifel | Buy |
2022-02-24 | Bestätigt | Wells Fargo | Overweight |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
2021-06-03 | Eingeleitet | Goldman | Buy |
2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
2021-01-11 | Eingeleitet | Stifel | Buy |
2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2020-06-12 | Eingeleitet | BTIG Research | Buy |
2020-02-21 | Eingeleitet | Guggenheim | Buy |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
2018-10-29 | Eingeleitet | JP Morgan | Overweight |
2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Guardant Health Inc. Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com
Is Guardant Health Inc. a good long term investmentFree Consultation - jammulinksnews.com
Cathie Wood’s ARK ETFs shift focus, buying NVIDIA and selling GUARDANT - Investing.com
What analysts say about Guardant Health Inc. stockConsistently superior profits - jammulinksnews.com
What drives Guardant Health Inc. stock priceExplosive wealth accumulation - jammulinksnews.com
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences - Benzinga
Guardant Health (GH): director Tariq Musa sells $5591 in stock By Investing.com - Investing.com South Africa
Guardant Health (GH): director Tariq Musa sells $5591 in stock - Investing.com
Guardant Health Director Sells 142 Shares at $48.2 Per Share on 2025-07-17. - AInvest
Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com
Lung Cancer Diagnostics Market Expansion Driven by Liquid - openPR.com
(GH) Technical Data - news.stocktradersdaily.com
User - FinancialContent
Evercore ISI Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - BioSpace
Guardant Health stock price target maintained at $60 by Evercore ISI - Investing.com Canada
What makes Guardant Health Inc. stock price move sharplyFree Stock Portfolio Optimization - beatles.ru
Press Release: Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - 富途牛牛
Quinn Emanuel Sanctioned For Ad Case 'Misrepresentations' - Law360
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know - MSN
US judge rebukes law firm Quinn Emanuel, awards $3 million sanction in Guardant case - Reuters
East Bay company looks to bring cancer insights to rheumatoid arthritisSan Francisco Business Times - The Business Journals
Precision Medicine Market worth $246.66 billion by 2029 with 11.1% CAGRRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Guardant Health Insider Sold Shares Worth $5,087,630, According to a Recent SEC Filing - MarketScreener
The 5 Most Interesting Analyst Questions From Guardant Health’s Q1 Earnings Call - Yahoo Finance
Is GH's Q1 2025 forecast achievable? - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer - The Lancet
Guardant Health’s Colorectal Cancer Screening Test Earns Another Honor - Medical Product Outsourcing
Precision Medicine: The Future of Healthcare? Companies Like Tempus AI, Guardant Health, and Exact Sciences Are Pioneering the Way - AInvest
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Benzinga
Guardant Health gets Breakthrough Device Designation from FDA for cancer detection test - Mugglehead Magazine
Medical Services Stock Near A Buy Point, It Just Needs A Boost - Investor's Business Daily
Guardant Health Elects Board and Approves Auditor - TipRanks
Guardant Health, Inc. (NASDAQ:GH) Looks Just Right With A 26% Price Jump - simplywall.st
Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing
Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine
Guardant Health director sells shares worth $157,573 By Investing.com - Investing.com UK
Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director sells shares worth $157,573 - Investing.com
Guardant Health Executives Sell Shares - TradingView
Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):